Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
NCT ID: NCT05182463
Last Updated: 2025-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
5000 participants
INTERVENTIONAL
2022-01-08
2029-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In recent years, different guidelines have not reached consensus on the need to initiate antiviral therapy for inactive CHB patients: In the guidelines of Asian Pacific Association for The Study of Liver(APASL)-2015 and American Association for the Study of Liver Diseases(AASLD)-2018, antiviral therapy is generally not recommended for this group of patients, and regular outpatient follow-up is recommended. Guideline of European Association for the Study of the Liver(EASL)-2017 suggests that people with a family history of cirrhosis and liver cancer at this stage could be treated with antiviral therapy even if they did not meet the indications of antiviral therapy. According to Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2019) of China, antiviral therapy is still recommended for some patients with inactive HBsAg carrier status who are HBV DNA positive and meet the treatment indications. Studies have shown that some patients in immune tolerance stage may enter the immune clearance stage and have hepatitis flare. Patients of inactive CHB have the potential to develop HBeAg-negative CHB, and studies of long-term follow-up in this population have indicated the risk of hepatocellular carcinoma. With the popularization of the concept of functional cure for chronic hepatitis B, more and more people with inactive CHB have a strong desire for treatment. In recent years, several studies have demonstrated that Pegylated-interferon therapy can achieve high functional cure rate in patients with inactive CHB.
The purpose of this study is to establish a national multi-center, prospective real world study to compare the efficacy of different antiviral treatment regimens for patients with inactive CHB and seek for the factors of functional cure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection
NCT02973646
Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
NCT02474316
The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg
NCT02893124
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
NCT01892241
Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues
NCT02362490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequential Combination Group
Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks, followed by combination therapy with peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
Peginterferon Alfa-2B
Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
Nucleoside Analogs
Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
Initial Combination Group
NAs combined with peginterferon are used for 12-24 weeks, followed by peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
Peginterferon Alfa-2B
Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
Nucleoside Analogs
Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
Whole-course Combination Group
NAs combined with peginterferon are used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
Peginterferon Alfa-2B
Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
Nucleoside Analogs
Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
Peginterferon Monotherapy Group
Peginterferon is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
Peginterferon Alfa-2B
Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
NAs Monotherapy Group
NAs is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
Nucleoside Analogs
Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peginterferon Alfa-2B
Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
Nucleoside Analogs
Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HBsAg is positive for more than 6 months
* Hepatitis B e antigen(HBeAg) is negative and anti-HBe is positive
* Serum HBV DNA is less than 2000 IU/mL
* Alanine aminotransferase(ALT) and/or Aspartate aminotransferase(AST) is normal
* No antiviral durg (including nucleos(t)ide analogue and interferon) was used before enrollment
* Good compliance and voluntarily signed informed consent
Exclusion Criteria
* Any indication of liver cirrhosis
* Coinfection with hepatitis A virus(HAV), hepatitis C virus(HCV), hepatitis D virus(HDV), hepatitis E virus(HEV) or human immunodeficiency virus(HIV)
* Combined with other liver diseases (including drug-related, alcoholic, autoimmune, genetic metabolic liver diseases, etc.)
* There are serious lesions in the important organs, such as heart, lung, kidney, brain and fundus
* Patients with autoimmune diseases, unstable diabetes or thyroid diseases(hyperthyroidism or hypothyroidism)
* Confirmed or suspected liver cancer or other malignant tumors
* Patients after or preparing for organ transplantation
* Peripheral blood white blood cell count \< 3.5×109/L and/or platelet count \< 80×109/L
* Under immunosuppressant treatment
* Pregnant or planned pregnancy in a short term or lactation patients
* Alcohol abuse (average alcohol intake is more than 40 g/d in males or 20g/d in women) or drug addicts
* Present or past history of mental or psychological diseases
* Other conditions that the investigators deem inappropriate for the study.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhiliang Gao
Director of the infectious diseases department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhiliang Gao, Doctor
Role: STUDY_CHAIR
Third Affiliated Hospital, Sun Yat-Sen University
Guizhou Zou
Role: PRINCIPAL_INVESTIGATOR
The Second Hospital of Anhui Medical University
Jiabin Li
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Anhui Medical University
Zhende Lin
Role: PRINCIPAL_INVESTIGATOR
Anxi County Hospital
Guoxin Hu
Role: PRINCIPAL_INVESTIGATOR
SHENZHEN HOSPITAL of PEKING UNIVERSITY
Youping Lin
Role: PRINCIPAL_INVESTIGATOR
Dongguan Binhai Bay Central Hospital
Sichun Yin
Role: PRINCIPAL_INVESTIGATOR
Dongguan Ninth People's Hospital
Songmei He
Role: PRINCIPAL_INVESTIGATOR
Dongguan People's Hospital
Zengjia Xu
Role: PRINCIPAL_INVESTIGATOR
Dongyuan People's Hospital
Hui Shen
Role: PRINCIPAL_INVESTIGATOR
DuShanZi People's Hospital
Haifei Luo
Role: PRINCIPAL_INVESTIGATOR
First People's Hospital of Foshan
Wenhua Zhang
Role: PRINCIPAL_INVESTIGATOR
Gansu Wuwei Tumor Hospital
Maosheng Wu
Role: PRINCIPAL_INVESTIGATOR
Guangdong Second Provincial People's Hospital
Dong Wei
Role: PRINCIPAL_INVESTIGATOR
Guangzhou Second traditional Chinese Medicine hospital
Wenli Chen
Role: PRINCIPAL_INVESTIGATOR
Guangdong Provincial People's Hospital
Bihua Gao
Role: PRINCIPAL_INVESTIGATOR
Beihai People's hospital
Guifang Tang
Role: PRINCIPAL_INVESTIGATOR
Nanxishan Hospital of Giang xi zhuang Autonomous Region
Huaiyu Song
Role: PRINCIPAL_INVESTIGATOR
THE PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTCNOMOUS REGION
Zhuxiang Zhao
Role: PRINCIPAL_INVESTIGATOR
The First Municipal Hospital of Guangzhou
Xihua Fu
Role: PRINCIPAL_INVESTIGATOR
Guangzhou Panyu Central Hospital
Runqi Luo
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital of Guangzhou Medical University
Shi Ouyang
Role: PRINCIPAL_INVESTIGATOR
Fifth Affiliated Hospital of Guangzhou Medical University
Chunlan Zhang
Role: PRINCIPAL_INVESTIGATOR
GUANGZHOU EIGHTH PEOPLE'S HOSPITAL GUANGZHOU MEDICAL UNIVERSITY
Riying Lv
Role: PRINCIPAL_INVESTIGATOR
Guigang city People's Hospital
Bigang Xiong
Role: PRINCIPAL_INVESTIGATOR
GuiYang Public Health Clinlcal Center
Hong Peng
Role: PRINCIPAL_INVESTIGATOR
the People's Hospital of Guizhou
Sufen Zhou
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Quan Zhang
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Hospital Of Guizhou Medical University
YongChao Xian
Role: PRINCIPAL_INVESTIGATOR
The Third People's Hospital of Guilin
Ganwen Li
Role: PRINCIPAL_INVESTIGATOR
The Third Affiliated Hospital of Sun Yat-Sen Unlversity Yuedong hospital
Jinyu Xia
Role: PRINCIPAL_INVESTIGATOR
The Fifth Affiliated Hospital, Sun Yat-sen University
Bihui Zhong
Role: PRINCIPAL_INVESTIGATOR
The First Afiliated Hospital Sun Yat-sen University
Minhui Xiao
Role: PRINCIPAL_INVESTIGATOR
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Wenjun Gao
Role: PRINCIPAL_INVESTIGATOR
Zhongshan Sencond People's Hospital
Gang Li
Role: PRINCIPAL_INVESTIGATOR
The fourth people's Hospital of Zibo
Yangwen Luo
Role: PRINCIPAL_INVESTIGATOR
Zunyi Medical College
Jie Chen
Role: PRINCIPAL_INVESTIGATOR
The Second People's Hospital OF YULIN
Xiaochao Qin
Role: PRINCIPAL_INVESTIGATOR
Red Cross Hospital of Yulin City
Wuhai Qin
Role: PRINCIPAL_INVESTIGATOR
teaditional chinese medicine hospital of YULIN
Hongshun Fan
Role: PRINCIPAL_INVESTIGATOR
Yuebei Second People's Hospital
Ming Jiang
Role: PRINCIPAL_INVESTIGATOR
Guilin Municipal Hospital of Traditonal
Feng Lin
Role: PRINCIPAL_INVESTIGATOR
HANNAN GENERAL HOSPITAL
Chengfang Zheng
Role: PRINCIPAL_INVESTIGATOR
Hainan Western Central Hospital
Zhentao Gu
Role: PRINCIPAL_INVESTIGATOR
Heyuan people's Hospital
Fan Li
Role: PRINCIPAL_INVESTIGATOR
THE PEOPLE'S HOSPITAL of HEZHOU
Qin Yan
Role: PRINCIPAL_INVESTIGATOR
Huazhong University of Science and Technology Union Shenzhen Hospital
Zhanzhou Lin
Role: PRINCIPAL_INVESTIGATOR
Huizhou Municipal Central Hospital
Hui Chen
Role: PRINCIPAL_INVESTIGATOR
Hepatobiliary Hospital Of JiLin
Xujing Liang
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Jinan University
Bin Liu
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Shunde Hospital of Jinan University
Changzheng Hu
Role: PRINCIPAL_INVESTIGATOR
Jiangmen Central Hospital
Xingchuan Wang
Role: PRINCIPAL_INVESTIGATOR
The 924th Hospital of the PLA joint Logistic support Force
Chengzu Lin
Role: PRINCIPAL_INVESTIGATOR
Jinjiang City Hospital
Guihua Su
Role: PRINCIPAL_INVESTIGATOR
the First People's Hopistal of Kashi
Yi Wang
Role: PRINCIPAL_INVESTIGATOR
Karamay Central Hospital of Xinjiang
Yuqin Xu
Role: PRINCIPAL_INVESTIGATOR
The 962th Hospital of the PLA joint Logistic support Force
Lingyi Zhang
Role: PRINCIPAL_INVESTIGATOR
Lanzhou University Second Hospital
Xiaorong Mao
Role: PRINCIPAL_INVESTIGATOR
LanZhou University
Hong Wan
Role: PRINCIPAL_INVESTIGATOR
Lanzhou University Second Hospital
Qian Guo
Role: PRINCIPAL_INVESTIGATOR
LIU ZHOU WORKER'S HOSPITAL
Liu He
Role: PRINCIPAL_INVESTIGATOR
LIU ZHOU PEOPLE'S HOSPITAL
Zhengxiao Zhao
Role: PRINCIPAL_INVESTIGATOR
LIU ZHOU TRADITIONAL CHINESE MEDICAL HOSPITAL
Yan Lincan
Role: PRINCIPAL_INVESTIGATOR
Long yan hospital of traditional Chinese medicine
Feng Min
Role: PRINCIPAL_INVESTIGATOR
army 73rd group military hospital
Xiqiu Zeng
Role: PRINCIPAL_INVESTIGATOR
Mudanjiang Kangan Hospital
Shuilin Sun
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital of Nanchang University
Xiaoping Wu
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Nanchang University
Keqin Zhang
Role: PRINCIPAL_INVESTIGATOR
The Ninth Hospital of Nanchang
Hong Li
Role: PRINCIPAL_INVESTIGATOR
Southern Medical University, China
Jianzhen Yao
Role: PRINCIPAL_INVESTIGATOR
Putian Hanjiang Hospital
Liqin Cai
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Putian City
Rongxian Qiu
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Hospital of Putian University
Sandu Liu
Role: PRINCIPAL_INVESTIGATOR
The People's Hospital Of QianNan
Qinghua Lu
Role: PRINCIPAL_INVESTIGATOR
The Fourth People's Hospital of Qinghai Province
Ying Deng
Role: PRINCIPAL_INVESTIGATOR
The Sixth Affiliated Hospital of Guangzhou Medical University
Xingnan Pan
Role: PRINCIPAL_INVESTIGATOR
Quanzhou Decheng hospital
Ruyi Guo
Role: PRINCIPAL_INVESTIGATOR
Quanzhou First Hospital
Wenke Li
Role: PRINCIPAL_INVESTIGATOR
Quanzhou Hospital of traditional Chinese Medicine
Huiwen Song
Role: PRINCIPAL_INVESTIGATOR
SanMing First Hospital
Xiulan Xue
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Xiamen University
Qianguo Mao
Role: PRINCIPAL_INVESTIGATOR
Xiamen Hospital of Traditional Chinese Medicine
Haidong Zhao
Role: PRINCIPAL_INVESTIGATOR
Xiamen Chang gung hospital
Yanhui Zu
Role: PRINCIPAL_INVESTIGATOR
Shan dong public Health Clinical Center
Ruilie Chen
Role: PRINCIPAL_INVESTIGATOR
Shantou Central Hospital
Shu Yang
Role: PRINCIPAL_INVESTIGATOR
Shenzhen Bao'an People's Hospital
Jun Chen
Role: PRINCIPAL_INVESTIGATOR
Shenzhen Third People's Hospital
Yanyao Yin
Role: PRINCIPAL_INVESTIGATOR
Shenzhen Luohu Hospitai of Traditional Chinese Medicine
Rongshan Fan
Role: PRINCIPAL_INVESTIGATOR
Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine
Guangdong Tong
Role: PRINCIPAL_INVESTIGATOR
SHEN ZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
Weize Zuo
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Shihezi University School of Medicine
Bin Zhou
Role: PRINCIPAL_INVESTIGATOR
Weihai Chest Hospital
Huanwei Zheng
Role: PRINCIPAL_INVESTIGATOR
Shijiazhuang Hospital of Traditional Chinese Medicine
Chuantiao Zhang
Role: PRINCIPAL_INVESTIGATOR
Shishi General Hospital
Qing Ye
Role: PRINCIPAL_INVESTIGATOR
Tianjin Third Central Hospital
Xin Chen
Role: PRINCIPAL_INVESTIGATOR
Tianjin First Hospital
Changxia Niu
Role: PRINCIPAL_INVESTIGATOR
Tianshui First people's hospital
Jiancheng Zhang
Role: PRINCIPAL_INVESTIGATOR
Tianshui traditional Chinese medicine hospital
Ruihai Zhu
Role: PRINCIPAL_INVESTIGATOR
Weifang People's Hospital
Zhushi Liang
Role: PRINCIPAL_INVESTIGATOR
The Third People's Hospital of Wuzhou
Qingming Zheng
Role: PRINCIPAL_INVESTIGATOR
Fujian Xianyou General Hospital
Xiaobo Lu
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Xinjiang Medical University
Xiaozhong Wang
Role: PRINCIPAL_INVESTIGATOR
Traditional Chinese Medicine Hospital of Xinjiang
Huanwen Chen
Role: PRINCIPAL_INVESTIGATOR
XING AN COUNTY PEOPLE'S HOSPITSL
Haifeng Yu
Role: PRINCIPAL_INVESTIGATOR
YANTAI QISHAN HOSPITAL
Shengtao Zeng
Role: PRINCIPAL_INVESTIGATOR
Yili Prefecture Infectious Disease Hospital
Lei Li
Role: PRINCIPAL_INVESTIGATOR
Anhui Provincial Hospital
Weibing Shi
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Anhui University of Chinese Medicine
Chuanmiao Liu
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Bengbu Medical University
Mei Cai
Role: PRINCIPAL_INVESTIGATOR
Cangzhou Third Hospital
Lijuan Guan
Role: PRINCIPAL_INVESTIGATOR
The 2nd Hospital of da qing City
Riwang Hu
Role: PRINCIPAL_INVESTIGATOR
The 4th People's Hospital of da tong city
Jianli Huang
Role: PRINCIPAL_INVESTIGATOR
Yongchun County Hospital
Yueyong Zhu
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Fujian Medical University
Minghua Lin
Role: PRINCIPAL_INVESTIGATOR
Mengchao Hepatobiliary Hospital of Hujian Medical University
Ming Li
Role: PRINCIPAL_INVESTIGATOR
No.2 People's Hospital of Fuyang City
Xianqiu Huang
Role: PRINCIPAL_INVESTIGATOR
Guidong People's Hospital of Guangxi Zhuang Autonomous Region
Liying Zhu
Role: PRINCIPAL_INVESTIGATOR
The Second Affiliated Hospital of Harbin Medical University
Lei Yu
Role: PRINCIPAL_INVESTIGATOR
The Fourth Affiliated Hospital of Harbin Medical University
Baoshan Yang
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Harbin Medical University
Yuguo Zhang
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Hebei Medical University
Xiaoli Hu
Role: PRINCIPAL_INVESTIGATOR
Heilongjiang provincial hospital
Weizhong Yan
Role: PRINCIPAL_INVESTIGATOR
Jilin Central General Hospital
Xinsheng Xie
Role: PRINCIPAL_INVESTIGATOR
Affiliated Hospital of Jiaxing University
Caihua Jiang
Role: PRINCIPAL_INVESTIGATOR
FUJIAN JIANOU HOSPITAL
Guoqi Hu
Role: PRINCIPAL_INVESTIGATOR
Jieshou City People's Hospital
Junmei Han
Role: PRINCIPAL_INVESTIGATOR
THE THIRD HOSPITAL OF JIN CHENG
Deshun Yu
Role: PRINCIPAL_INVESTIGATOR
JIN CHENG PEOPLE'S HOSPITAL
Jianqi Lian
Role: PRINCIPAL_INVESTIGATOR
Tang-Du Hospital
Jiuping Wang
Role: PRINCIPAL_INVESTIGATOR
Xijing Hospital
Zhengjun Xu
Role: PRINCIPAL_INVESTIGATOR
The 910th Hospital
Fenxiang Li
Role: PRINCIPAL_INVESTIGATOR
LIN FEN THIRD PEOPLE'S HOSPITAL
Tonghe Wu
Role: PRINCIPAL_INVESTIGATOR
THE SECOND HOSPITAL OF LONGYAN
Fen Wu
Role: PRINCIPAL_INVESTIGATOR
JIANYANG FIRST HOSPITAL OF NANPING
Yun Wu
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Hospital of Inner Mongolia Medical University
Houxiong Lin
Role: PRINCIPAL_INVESTIGATOR
Ningde Municipal Hospital of Ningde Normal University
Yongyue Deng
Role: PRINCIPAL_INVESTIGATOR
Zhongshan Hospital Xiamen University
Xiao Wang
Role: PRINCIPAL_INVESTIGATOR
Digestive Diseases Hospital of Shandong First Medical University
Huaizhang Li
Role: PRINCIPAL_INVESTIGATOR
Shanxi Traditional Chinese Medical Hospital
Liaoyun Zhang
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Shanxi Medical University
Binhong Fu
Role: PRINCIPAL_INVESTIGATOR
Shaowu Municiple Hospital of Fujian Province
Ye Gu
Role: PRINCIPAL_INVESTIGATOR
The Sixth People's Hospital of Shenyang
Ying Guo
Role: PRINCIPAL_INVESTIGATOR
The Third People's Hospital of Taiyuan
Ping Li
Role: PRINCIPAL_INVESTIGATOR
Tianjin Second People's Hospital
Zhifeng Li
Role: PRINCIPAL_INVESTIGATOR
TONG LIAO INFECTIOUS DISEASES HOSPITAL
Jingning Zhao
Role: PRINCIPAL_INVESTIGATOR
SINOPHARM TONGMEI GENERAL HOSPITAL
Shuangsuo Dang
Role: PRINCIPAL_INVESTIGATOR
The Second Affiliated Hospital of Ｘi'an Jiaotong University
Shumei Lin
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Ｘi'an Jiaotong University
Hongxin Pu
Role: PRINCIPAL_INVESTIGATOR
Yanbian University Hospital
Li Zhang
Role: PRINCIPAL_INVESTIGATOR
The Sixth hospital of Handan City
Yongmei Lin
Role: PRINCIPAL_INVESTIGATOR
Hanzhong 3201 Hospital
Chunzhi Su
Role: PRINCIPAL_INVESTIGATOR
Hebei Hospital of Traditional Chinese Medicine
Mingxia Jiang
Role: PRINCIPAL_INVESTIGATOR
Jiamusi Infectious Disease Hospital
Chengrun Xu
Role: PRINCIPAL_INVESTIGATOR
Southeast Hospital affiliated to Xiamen University
Ying Dai
Role: PRINCIPAL_INVESTIGATOR
The 7th Hospital of Qiqihar
Jiansheng Huang
Role: PRINCIPAL_INVESTIGATOR
Wuping County Hospital
Qingrui Peng
Role: PRINCIPAL_INVESTIGATOR
Xiapu County Hospital
Weixin Wang
Role: PRINCIPAL_INVESTIGATOR
The 2nd Affiliated Hospital of YCU
Zhigang Lin
Role: PRINCIPAL_INVESTIGATOR
SanMing Yongan General Hospital
Shihong Wu
Role: PRINCIPAL_INVESTIGATOR
Yuncheng Central Hospital
Zhongfu Zhao
Role: PRINCIPAL_INVESTIGATOR
Changzhi Medical College
Yi Zheng
Role: PRINCIPAL_INVESTIGATOR
Xinhua Hospital of Zhejiang Province
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Li MH, Xie Y, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Hu LP, Hua WH, Song SJ, Zhang SF, Cheng J, Xu DZ. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol. 2016 May 28;8(15):637-43. doi: 10.4254/wjh.v8.i15.637.
Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, He Z, Shen C, Chen X. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017 Oct;66(4):1058-1066. doi: 10.1002/hep.29213. Epub 2017 Aug 26.
Wu F, Lu R, Liu Y, Wang Y, Tian Y, Li Y, Li M, Wang W, Zhang X, Jia X, Dang S. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver Int. 2021 Sep;41(9):2032-2045. doi: 10.1111/liv.14897. Epub 2021 May 26.
Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013 May;58(5):853-60. doi: 10.1016/j.jhep.2012.12.006. Epub 2012 Dec 13.
Huang Y, Qi M, Liao C, Xun J, Zou J, Huang H, Long LY, Chen J, Fan X, Chen R. Analysis of the Efficacy and Safety of PEGylated Interferon-alpha2b Treatment in Inactive Hepatitis B Surface Antigen Carriers. Infect Dis Ther. 2021 Dec;10(4):2323-2331. doi: 10.1007/s40121-021-00511-w. Epub 2021 Aug 4.
Zeng QL, Yu ZJ, Shang J, Xu GH, Sun CY, Liu N, Li CX, Lv J, Liu YM, Liang HX, Li ZQ, Pan YJ, Hu QY, Li W, Zhang DW, Wang FS. Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels. Open Forum Infect Dis. 2020 Jun 3;7(6):ofaa208. doi: 10.1093/ofid/ofaa208. eCollection 2020 Jun.
Chang LJ, Hao CQ, Rao GR, Xu LL, Li J, Cheng Y, Zheng LJ, Wu CW, Chen HX, Chen ZR, Lian JQ, Wu SH, Luo LM, Zhang WL, Zhang Y. Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-alpha-2b-based therapy: a multicenter pilot study. Virol J. 2025 May 19;22(1):146. doi: 10.1186/s12985-025-02761-3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
[2021]02-373-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.